Minerva Pharma Consulting
ActiveMinerva Pharma Consulting has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3k and a net result of €98k. Equity is shrinking by ~48.1% per year and would, assuming unchanged policy, indicatively turn negative around fiscal year 2026. Its solvency ranks better than 15% of 524 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.9% (low).
Checked score
Score 2025
64
/ 100
Healthy
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency26▼-74
Growth58▼-20
Track record94
Bankruptcy probability, 12 months
0.9%
Low
0%0.5%1.5%4%10%≥ 25%
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Sector 72
lower
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
1.1%
Return on assets
36%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 15% of 524 sector peers (2025).
NBB · sector comparisonPosition among 524 sector peers
Solvency
better than 15%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-02-2026, 179 days ahead of the deadline.
NBB · 3 filingsDeviation from the deadline
2025
179 d early
2024
28 d early
2023
16 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
23-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€3k▼ 98.1%
2024 · €160k
2023: €80k
2024: €160k
2023 → 2025
Total assets
€272k▲ 57.5%
2024 · €173k
2023: €113k
2024: €173k
2023 → 2025
Net result
€98k▲ 21.6%
2024 · €81k
2023: €78k
2024: €81k
2023 → 2025
Working capital
€-3k
2024 · €155k
2023: €75k
2024: €155k
2023 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line202320242025Trend
Equity€80k-€160k▲ 99.8%€3k▼ 98.1%
Operating result€99k-€105k▲ 5.6%€127k▲ 21.0%
Net result€78k-€81k▲ 3.8%€98k▲ 21.6%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has risen two years in a row; 2025 is 21% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €272k
Fixed assets
€6k▲ 33.3%
Current assets
€266k▲ 58.1%
Equity and liabilities €272k
Equity
€3k▼ 98.1%
Debt
€269k▲ 1,932%
The debt ratio rises from 7.7% to 98.9%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€127k▲
2024 · €105k
Cash flow
€99k▲
2024 · €81k
Solvency
1.1%▼
2024 · 92.3%
Current ratio
0.99▼
2024 · 12.72
Quick ratio
0.99▼
2024 · 12.72
Debt / equity
89.71▲
2024 · 0.08
ROA
36.0%▼
2024 · 46.6%
Interest coverage
77.49▲
2024 · 50.04
Debt
€269k▲
2024 · €13k
Debt ≤ 1 year
€269k▲
2024 · €13k
Income taxes
€27k▲
2024 · €22k
A ratio outside any meaningful range has been withheld (balance sheet total €272k, equity €3k).
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€173k€272k▲
Fixed assets21/28€4k€6k▲
Tangible fixed assets22/27€4k€6k▲
Furniture and vehicles24-€2k
Other tangible fixed assets26€4k€4k▼
Current assets29/58€169k€266k▲
Amounts receivable within one year40/41€11k€17k▲
Trade receivables40€10k€16k▲
Other amounts receivable41€1k€1k▼
Cash at bank and in hand54/58€154k€246k▲
Deferred charges and accrued income490/1€4k€3k▼
Equity and liabilities
Total equity and liabilities10/49€173k€272k▲
Equity10/15€160k€3k▼
Contributions10/11€3k€3k=
Reserves13€157k€0▼
Distributable reserves133€157k€0▼
Profit (loss) carried forward14€0€0=
Amounts payable17/49€13k€269k▲
Amounts payable within one year42/48€13k€269k▲
Trade debts44€3k€2k▼
Suppliers440/4€3k€2k▼
Taxes, remuneration and social security45€10k€51k▲
Taxes450/3€10k€51k▲
Other amounts payable47/48€601€216k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€508€823▲
Other operating charges640/8€391€63▼
Gross operating margin9900€105k€127k▲
Operating profit (loss)9901€105k€127k▲
Financial income75/76B€25€285▲
Recurring financial income75€25€285▲
Financial charges65/66B€2k€2k▼
Recurring financial charges65€2k€2k▼
Profit (loss) for the period before taxes9903€103k€125k▲
Income taxes67/77€22k€27k▲
Profit (loss) for the period9904€81k€98k▲
Profit (loss) for the period to be appropriated9905€81k€98k▲
Appropriation of the result
Profit (loss) to be appropriated9906€81k€98k▲
Transfer from equity791/2-€157k
Transfer to equity691/2€80k€0▼
To other reserves6921€80k€0▼
Profit to be distributed694/7€859€255k▲
Return on contributions (dividend)694€859€255k▲
The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
02-02
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2023net €98k ▲21.6%
Operating result €127k, net result €98k, both a record.
03-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Liquidity quadruplescurrent ratio 12.72
Current ratio from 3.29 to 12.72; short-term debt falls from €33k to €13k.
31-12
Financial
Equity above €150kEq €160k ▲99.8%
2 profitable years in a row build equity to €160k.
15-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Keerbergen · 1 establishment unit since 2023
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Viooltjesweg 193140 KeerbergenGround area
1,087 m²
Building footprint
156 m²
Volume, LiDAR
107 m³
Parcel 24472G0256/00V000, Flanders · tallest building 16.5 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Minerva Pharma Consulting
since 20232.342.008.679
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24472G0256/00V000 | Flanders | 1,087 m² | 1 · 156 m² | 16.5 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
BIOCLI CONSULT
BE 0770.990.147
Jurbise · Eq €3k
Snowcap
BE 0782.424.863
Gent · Eq €4k
Obvio Laboratories
BE 0763.445.923
Ukkel · Eq €3k
WE ARE REBEL
BE 1022.159.373
Evere · Eq €4k
Education and Edition for Science
BE 0750.847.207
Schaarbeek · Eq €2k
Of 1,177 companies in sector 72109 we hold annual accounts for 715. 96 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded24-02-2023
Fiscal year end31-12
Activities, NACEBEL
72109Other research and development on natural sciences
70200Business and other management consultancy
70210Activities of head offices; management consultancy activities
70220Business consulting
73110Advertising agencies
73300Public relations and communication consultancy
82990Other business support services
85599Other education
Sources
Crossroads Bank for EnterprisesNational Bank · 3 filingsAddress and cadastre registers
Data from official sources, last processed on 23-09-2026. Scores and ratios are computed by Checked and are not a credit decision.